Scarica l'app Stockscreener
8.92
4.90%
-0.46
Precedente Chiudi:
$9.38
Aprire:
$8.92
Volume 24 ore:
1,207
Relative Volume:
0.42
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.16%
1M Prestazione:
-17.79%
6M Prestazione:
-38.53%
1 anno Prestazione:
-43.79%
Intervallo 1D:
$8.841
$8.965
Intervallo di 1 settimana:
$8.841
$9.87
Portata 52W:
$8.841
$16.27
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Nome
Range Cancer Therapeutics Etf
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CNCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
8.92 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
263.96 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
536.70 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
540.07 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
210.85 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
450.66 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Borsa (CNCR) Ultime notizie
Best Stocks Under $20 Right Now - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
VOO ETF News, 3/14/2025 - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail
12 Best Stock Scanners and Screeners in March 2025 in March 2025 - Benzinga
Broaden Your ETF Exposure With These 3 Overlooked Funds - The Globe and Mail
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Dividend Investing in Canada: Trends, Leaders, and ETF Picks - The Globe and Mail
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio - Nasdaq
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
CIBC Asset Management announces CIBC ETF cash distributions for February 2025 - The Globe and Mail
(CNCR) Trading Signals - Stock Traders Daily
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail
Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
When (CNCR) Moves Investors should Listen - Stock Traders Daily
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Looking for Gold Exposure in 2025? 3 ETFs to Consider - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer (LPTX) - Seeking Alpha
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts (BDTX) - Seeking Alpha
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Science & Technology | TBR News Media | Page 2 - TBR News Media
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises - Yahoo Finance
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields (NVCR) - Seeking Alpha
Range Cancer Therapeutics Etf Azioni (CNCR) Dati Finanziari
Non sono disponibili dati finanziari per Range Cancer Therapeutics Etf (CNCR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):